NCT01973998View on ClinicalTrials.gov

Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization

PHASE3CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 10, 2017

Study Completion Date

November 30, 2017

Conditions

COPD

Interventions

DRUG

Roflumilast

PDE4 inhibitor

DRUG

Placebo

Inactive substance.

Trial Locations (1)

19140

Temple University Hospital, Philadelphia

Sponsors

Collaborators (1)

Forest Laboratories

All Listed Sponsors

collaborator

Forest Laboratories

INDUSTRY

lead

Temple University

OTHER

NCT01973998 - Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization | Biotech Hunter | Biotech Hunter